Experiences in adjuvant immunotherapy of melanoma with BCG substrain Jena S 4.
Wätzig
V
V
Zureck
A
A
D001500:BCG Vaccine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D005500:Follow-Up Studies; D006801:Humans; D008545:Melanoma / Q000601:surgery / Q000628:therapy*
D001500:BCG Vaccine